Sunitinib and other targeted therapies for renal cell carcinoma.
Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years.
Department of Medical Oncology, St Bartholomew's Hospital London, Barts and the London NHS trust, Charterhouse Square, London, UK. thomas.polwes@bartsandthelondon.nhs.uk
T
T
Powles
S
S
Chowdhury
R
R
Jones
M
M
Mantle
P
P
Nathan
A
A
Bex
L
L
Lim
T
T
Hutson
D014408:Biomarkers, Tumor / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D011379:Prognosis; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D014408:Biomarkers, Tumor; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D000077210:Sunitinib
Cancer. 2008 Oct 1;113(7):1552-8
18720362
Lancet. 2007 Dec 22;370(9605):2103-11
18156031
J Clin Oncol. 2008 Aug 1;26(22):3743-8
18669461
Lancet Oncol. 2009 Aug;10(8):757-63
19615940
Nat Rev Clin Oncol. 2010 May;7(5):277-88
20368728
Lancet Oncol. 2009 Oct;10(10):992-1000
19796751
J Clin Oncol. 2010 May 1;28(13):2131-6
20368560
J Clin Oncol. 2008 Oct 1;26(28):4572-8
18824708
J Clin Oncol. 2006 Dec 10;24(35):5601-8
17158546
J Clin Oncol. 2009 Aug 1;27(22):3584-90
19487381
BMC Cancer. 2009 Mar 12;9:82
19284623
J Urol. 2003 Aug;170(2 Pt 1):588-92
12853836
J Clin Oncol. 2009 Dec 1;27(34):5794-9
19826129
J Clin Oncol. 2009 Sep 20;27(27):4462-8
19652060
Anticancer Res. 2005 Mar-Apr;25(2A):1109-13
15868953
J Clin Oncol. 2008 Jan 1;26(1):127-31
18165647
Nat Rev Cancer. 2008 Aug;8(8):592-603
18650835
J Urol. 2009 Jul;182(1):29-34; discussion 34
19447417
Cancer Cell. 2004 Nov;6(5):507-16
15542434
J Clin Oncol. 2010 Jan 20;28(3):475-80
20008644
J Clin Oncol. 2009 Mar 10;27(8):1280-9
19171708
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Br J Cancer. 2010 Mar 2;102(5):803-9
20145618
Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
19967539
Cancer Res. 2006 Feb 1;66(3):1500-8
16452206
J Clin Oncol. 2008 Nov 20;26(33):5422-8
18936475
N Engl J Med. 2001 Dec 6;345(23):1655-9
11759643
Lancet. 2008 Aug 9;372(9637):449-56
18653228
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
Lancet Oncol. 2007 Nov;8(11):975-84
17959415
Mol Cell. 2006 Apr 21;22(2):159-68
16603397
Br J Haematol. 2008 Jul;142(3):361-78
18540942
J Clin Oncol. 2009 Sep 1;27(25):4068-75
19652072
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530